Noxopharm (ASX: NOX) Reports Promising Results from Innovative Pancreatic Cancer Therapy

Key Highlights:

- Noxopharm’s CRO-67 significantly reduces pancreatic tumour growth and metastasis.

- The drug demonstrated a dual-cell therapy effect, targeting both tumour and barrier cells.

- CRO-67 was well-tolerated in preclinical studies, showing no adverse effects.

Noxopharm (ASX: NOX) has announced breakthrough results from its preclinical studies on CRO-67, an innovative drug targeting pancreatic cancer. This disease, notoriously difficult to treat due to its protective barrier of cells, has shown significant vulnerability to CRO-67's dual-cell therapy approach. The drug not only reduced tumour volume by 39.15% but also decreased the spread of cancer cells to other organs by 45.77%, highlighting its potential as a game-changer in oncology.

Dr. Gisela Mautner, CEO of Noxopharm, stated, “These results are encouraging as they show CRO-67's dual-cell therapy effect in stringent pancreatic cancer models. This data will guide the next steps in our project and be crucial in future regulatory processes.”

The significance of this development cannot be overstated, as pancreatic cancer has one of the poorest survival rates, with limited effective treatments available. Noxopharm’s CRO-67, showing both efficacy and safety, could mark a pivotal advancement in the fight against this devastating disease.

As of 2:47 PM, 14th August 2024, $NOX shares are trading at A $0.028.